Skip to content

A randomized, double-blind, placebo-controlled study of crecoxib as an adjunctive therapy for schizophrenia

A randomized, double-blind, placebo-controlled study of crecoxib as an adjunctive therapy for schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041403
Enrollment
Unknown
Registered
2020-12-25
Start date
2019-04-08
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

celecoxib group:Combined celecoxib 200mg/d
control group:placebo

Sponsors

Ethics Committee of the Second Affiliated Hospital of Xinxiang Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. The subjects who can effectively communicate with researchers and research staff, fill in research related materials, understand the informed consent form, and sign the written informed consent form before any research evaluation; 2. Male or female, hospitalized patients, 55 years old >= 16 years old; 3. Patients diagnosed by two professional psychiatrists as meeting DSM-IV diagnostic criteria for schizophrenia, and PANSS score >= 60; 4. Patients who did not receive long-acting antipsychotics or injections within at least two months before enrollment or who did not receive antipsychotics within one week, and the course of disease was less than 6 months; 5. All patients without any infection or autoimmune disease within two weeks; 6. Subjects who have been educated for more than 6 years; 7. Subjects with IQ >= 70; 8. Han population.

Exclusion criteria

Exclusion criteria: 1. Non schizophrenic patients with other mental diseases (determined by SCID); 2. Patients with severe or unstable diseases, or severe inflammatory or immune diseases, including heart disease, epilepsy, liver and kidney disease, diabetes, aplastic anemia, systemic lupus erythematosus or asthma; 3. Patients who used anti-inflammatory drugs (such as celecoxib, p-lactam antibiotics), hormones or immunosuppressants within 6 months before entering the study; 4. Patients with contraindications of celecoxib treatment; 5. Women of childbearing age who have planned pregnancy, pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
PANSS;indoleamine2,3-dioxygenase;tumor necrosis factor a;interleukin 1ß;interleukin 4;interleukin 6;interleukin 17;Interferon ?;

Countries

China

Contacts

Public ContactLuxian Lyu

The Second Affiliated Hospital of Xinxiang Medical College

lvx928@126.com+86 18537320007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026